Pfizer to combine off-patent drug business with Mylan
As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan– a generic drugmaker. Pfizer shareholders would own
New Venture
SCC Times
Bringing you the Best Analytical Legal News